Clinical trials: Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
This is a phase II study evaluating a new combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial phase with the drug Bemotuzumab plus standard chemotherapy and anlotinib…
- Trial name
- NCT07358676
- Testing
- Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Extensive-stage Small-cell Lung Cancer
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
This is a single arm, multi-center, phase II trial to evaluate the efficacy, and safety of adebrelimab combined with famitinib and chemotherapy for the treatment of first-line extensive stage small cell lung cancer.
- Trial name
- NCT06306560
- Testing
- adebrelimab, famitinib, chemotherapy
- Volunteers
- 40 people
- Sponsor
- Harbin Medical University
Lung Cancer, Metastatic Cancer
11C Topotecan PET Imaging
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET scan) using 11C topotecan, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Conditions
- Lung Cancer, Metastatic Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00253461
- Testing
- computed tomography, positron emission tomography, 11C topotecan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Small Cell, Lung Neoplasms
Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer
Most patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and prophylactic cranial irradiation, have persistent intrathoracic disease.
- Trial name
- NCT02675088
- Testing
- high-dose TRT, standard-dose TRT
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- Chinese Academy of Medical Sciences
Small Cell Lung Carcinoma
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC…
- Trial name
- NCT04938817
- Testing
- coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830
- Where
- 48 sites in United States, Australia and 10 more
- Volunteers
- 110 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer Extensive Stage
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the…
- Trial name
- NCT04967625
- Testing
- Sintilimab, Anlotinib hydrochloride
- Volunteers
- 23 people
- Sponsor
- Zhejiang Cancer Hospital
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma
- Trial name
- NCT01155258
- Testing
- temsirolimus, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and…
- Trial name
- NCT07564401
- Testing
- DJI136
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Small Cell
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I.
- Trial name
- COMBAT (NCT00826644)
- Testing
- Belotecan, Etoposide, Cisplatin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Chonnam National University Hospital
Extensive-Stage Small Cell Lung Cancer
Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer
This is an investigator-initiated, single-center, observational, noninterventional retrospective real-world cohort study evaluating the effectiveness and safety of tarlatamab as second-line or later-line therapy in Chinese adults…
- Trial name
- NCT07885332
- Testing
- Tarlatamab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Ruijin Hospital
SCLC,Extensive Stage
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
This is an open-label, single arm, phase 2 trial enrolling patients with untreated Extensive-Stage Small-Cell Lung Cancer (ES SCLC), with a strong translational attitude.
- Trial name
- THOR (NCT05623319)
- Testing
- Pembrolizumab/Olaparib
- Where
- 12 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
This is an open label, phase 2 clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetic (PK) profile, and immunogenicity of QL1706 plus carboplatin and etoposide as first-line therapy in patients with…
- Trial name
- NCT05309629
- Testing
- QL1706, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
This is a non-interventional, multicenter, prospective observational study and registry of standard clinical practice in patients with Extensive Stage-Small Cell Lung Cancer (ES-SCLC) receiving 1st line treatment with Durvalumab…
- Trial name
- DRIVE (NCT05761977)
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Hellenic Cooperative Oncology Group
SCLC, Extensive Stage, Bayesian
Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer
This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol.
- Conditions
- SCLC, Extensive Stage, Bayesian, Metronomic Chemotherapy
- Trial name
- NCT07698054
- Testing
- Toripalimab; Etoposide
- Volunteers
- 130 people
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Cancer
Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC
CLINATEZO cohort will evaluate overall survival, real world progression-free survival, best response and duration of treatment in patients with advanced, metastatic Small Cell Lung Cancer (SCLC) who received atezolizumab combined…
- Trial name
- CLINATEZO (NCT04920981)
- Testing
- atezolizumab
- Where
- 2 sites in France
- Volunteers
- 518 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Exisulind may make tumor cells more sensitive to chemotherapy.
- Trial name
- NCT00041054
- Testing
- carboplatin, etoposide, exisulind
- Where
- 83 sites in United States, Canada and 1 more
- Volunteers
- 41 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chloroquinoxaline sulfonamide in treating patients who…
- Trial name
- NCT00008372
- Testing
- chloroquinoxaline sulfonamide
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung…
- Conditions
- Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
- Trial name
- NCT07625644
- Testing
- BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 550 people
- Sponsor
- SystImmune Inc.
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Small Cell Lung Carcinoma
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Cyclic, 5-day calorie restriction is a safe metabolic intervention when combined with standard therapies in cancer patients, favorably reshaping peripheral blood and intratumor metabolism and immunity in a way that may improve…
- Trial name
- FASTIMMUNE (NCT05703997)
- Testing
- Cyclic, 5-day calorie restriction, Atezolizumab
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano